Regencell Bioscience Holdings Limited: January 2025 Form 6-K Insights & Lock-Up Extension

Here are the key insights and important information extracted from the financial report of Regencell Bioscience Holdings Limited, as filed in the Form 6-K:

1. Company Information:

• Name: Regencell Bioscience Holdings Limited
• Headquarters: 9/F Chinachem Leighton Plaza, 29 Leighton Road, Causeway Bay, Hong Kong.
• Commission File Number: 001-40617.

2. Filing Type:

• This report is a Form 6-K, which is used by foreign private issuers to disclose information that is of importance to shareholders and the SEC.

3. Reporting Period:

• The report is dated January 15, 2025, and pertains to the month of January 2025.

4. Lock-up Agreement:

• All directors and employees who were previously granted stock options have agreed to an extension of their lock-up period for an additional 15 months, until April 20, 2026.
• This is an extension of a prior lock-up that was set to expire on January 20, 2025.
• The lock-up undertaking restricts the sale of their shares until the new expiration date.

5. Lock-up Document:

• A form of the lock-up undertaking is attached as Exhibit 99.1.

6. Management Signature:

• The report is signed by Yat-Gai Au, who is the Chief Executive Officer and Chairman of the Board of Directors.

7. Exhibit Index:

• The report includes an exhibit (Exhibit 99.1) that describes the form of the lock-up undertaking.

This information indicates a commitment by the company's leadership and employees to maintain the stability of the company’s share price by restricting their ability to sell shares for an extended period. This often reflects positively on investor confidence, suggesting that insiders believe in the company's future prospects.